Generation and Characterization of Functional Cardiomyocytes Derived from Human T Cell-Derived Induced Pluripotent Stem Cells

Tomohisa Seki1,2, Shinsuke Yuasa1, Dai Kusumoto1, Akira Kunitomi1, Yuki Saito1, Shugo Tohyama1,2, Kojiro Yae1, Yoshikazu Kishino1, Marina Okada1, Hisayuki Hashimoto1, Makoto Takei1, Toru Egashira1, Masaki Kodaira1, Yusuke Kuroda1, Atsushi Tanaka1, Shinichiro Okata1, Tomoyuki Suzuki1, Mitsushige Murata1, Jun Fujita1, Keiichi Fukuda1*

1 Department of Cardiology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 2 Japan Society for the Promotion of Science, Chiyoda-ku, Tokyo, Japan

Abstract

Induced pluripotent stem cells (iPSCs) have been proposed as novel cell sources for genetic disease models and revolutionary clinical therapies. Accordingly, human iPSC-derived cardiomyocytes are potential cell sources for cardiomyocyte transplantation therapy. We previously developed a novel generation method for human peripheral T cell-derived iPSCs (TiPSCs) that uses a minimally invasive approach to obtain patient cells. However, it remained unknown whether TiPSCs with genomic rearrangements in the T cell receptor (TCR) gene could differentiate into functional cardiomyocyte in vitro. To address this issue, we investigated the morphology, gene expression pattern, and electrophysiological properties of TiPSC-derived cardiomyocytes differentiated by floating culture. RT-PCR analysis and immunohistochemistry showed that the TiPSC-derived cardiomyocytes properly express cardiomyocyte markers and ion channels, and show the typical cardiomyocyte morphology. Multiple electrode arrays with application of ion channel inhibitors also revealed normal electrophysiological responses in the TiPSC-derived cardiomyocytes in terms of beating rate and the field potential waveform. In this report, we showed that TiPSCs successfully differentiated into cardiomyocytes with morphology, gene expression patterns, and electrophysiological features typical of native cardiomyocytes. TiPSCs-derived cardiomyocytes obtained from patients by a minimally invasive technique could therefore become disease models for understanding the mechanisms of cardiac disease and cell sources for revolutionary cardiomyocyte therapies.

Introduction

Severe heart failure is a progressive and treatment-resistant disease for which the only complete cure is heart transplantation [1]. In addition, many of the etiological problems leading to heart failure remain unsolved. Direct reprogramming of somatic cells to produce induced pluripotent stem cells (iPSCs) through the forced expression of several embryonic stem (ESC)-specific transcription factors is a prominent recent advance in stem cell biology [2], and human iPSCs hold great promise as new tools for investigating mechanism of disease and as cell sources for transplantation therapy [3]. Human iPSC-derived cardiomyocytes (iPSC-CMs) are thus potential future cell sources for novel cardiomyocyte transplantation therapies for severe heart failure [4,5].

Successful differentiation of human iPSCs into cardiomyocytes was first reported in 2009 [6]. Subsequently, human iPSC-CMs have been developed as in vitro models for cardiac electrophysiological studies and drug screening [7]. Disease modeling of cardiac disease using patient-derived iPSC-CMs was also reported in the field of inherited arrhythmia diseases [8–12] and inherited cardiomyopathies [13–15]. Furthermore, iPSC-CMs have been engrafted successfully into the hearts of experimental animals [16] and used to improve cardiac function after ischemic cardiomyopathy in a porcine model [17]. Thus, research using iPSC-CM will be important in clarifying disease mechanisms and establishing novel therapies [18–20].

A wide range of donor cell types, gene-introducing vehicles, and combinations of reprogramming factors have been used for generating iPSCs [21]; however, minimally invasive methods have the significant practical advantage for generating iPSCs from patients [22]. We previously reported the generation of T cell-derived iPSCs (TiPSCs), which involves a non-invasive method and requires only small volumes of peripheral blood, which means an increased number of eligible patients [23]. Further to this, the present study sought to clarify whether TiPSCs with genomic T cell receptor (TCR) gene rearrangements could differentiate into functional cardiomyocyte in vitro, by examining the morphology, gene expression pattern, and electrophysiological properties of TiPSC-CMs.
Materials and Methods

Cell culturing

The human TiPSC lines, T05 and T07 were generated from human peripheral T cells by introducing OCT3/4, SOX2, KLF4, and c-MYC with Sendai virus vectors [23]. The human iPSC line, F16 was generated from human fibroblasts by introducing OCT3/4, SOX2, KLF4, and c-MYC with retrovirus vectors [24]. The human ESC line (Khes-2) [25] was obtained from the Department of Development and Differentiation, Institute for Frontier Medical Sciences, Kyoto University and used in conformity with the Guidelines for Derivation and Utilization of Human Embryonic Stem Cells of the Ministry of Education, Culture, Sports, Science, and Technology, Japan. These cell lines were cultured in human iPSC medium consisting of DMEM/F12 medium (Invitrogen) supplemented with 20% Knock-out Serum Replacement (KSR; Invitrogen), 1 mM L-glutamine, 1 mM non-essential amino acids, 0.1 mM β-mercaptoethanol, 50 U penicillin and 50 mg/ml streptomycin (Invitrogen), and 4 ng/ml basic fibroblast growth factor (bFGF; WAKO). The human iPSC medium was changed every other day until the colonies were picked. The iPSCs and ESCs were maintained on irradiated mouse embryonic fibroblast (MEF) feeder cells [26] from wild-type ICR mice in growth factor (bFGF; WAKO). The human iPSC medium was 50 mg/ml streptomycin (Invitrogen), and 4 ng/ml basic fibroblast growth factor (bFGF; WAKO). The human iPSC medium was changed every other day until the colonies were picked. The iPSCs and ESCs were maintained on irradiated mouse embryonic fibroblast (MEF) feeder cells [26] from wild-type ICR mice in human iPSC medium which was changed every 2–3 days, and the cells were passaged using 1 mg/ml collagenase IV (Invitrogen) every 5–6 days.

In vitro differentiation of iPSCs and ESCs

The iPSCs and ESCs were harvested using 1 mg/ml collagenase IV, and transferred to ultra-low attachment plates (Corning) in differentiation medium. The differentiation medium consisting of Minimum Essential Medium Alpha Medium (Gibco) supplemented with 2 mM L-glutamine (Invitrogen), 0.1 mM non-essential amino acids (Sigma), 0.1 mM 2-mercaptoethanol, 50 U/ml penicillin and 50 mg/ml streptomycin (Invitrogen), and 20% fetal bovine serum (Gibco). The medium was replaced every second or third day. To promote cardiac differentiation, recombinant human Wnt3a was added to the differentiation medium for the first 4 days of culture at 100 ng/ml [27]. The time window of differentiation for analyzing the beating embryoid bodies (EBs) and cardiomyocytes was 30–60 days from starting the differentiating conditions.

Reverse transcription-polymerase chain reaction (RT-PCR)

Total RNA was isolated from cells using TRIZOL reagent (Invitrogen) and RNasefree DNase I (Qiagen), according to the manufacturer’s instructions. The concentration and purity of the RNA were determined using an ND-1000 spectrophotometer (Nanodrop). The cDNA was synthesized using the Transcriptor First-Strand Synthesis System (Invitrogen). PCR was performed with Taq (TAKARA). The primers used for PCR are listed in Table S1.

Quantitative RT-PCR analysis

Total RNA was isolated and used for reverse transcription with random primers as described by the manufacturer. Real-time quantitative RT-PCR was performed using MX3000P (Stratagene), with SYBR Premix ExTaq (TAKARA). The amount of mRNA was normalized to GAPDH mRNA. Primer sequences and cycling conditions are listed in Table S1.

Immunofluorescence

The differentiated cardiomyocytes plated on fibronectin-coated dishes were washed once with PBS, and fixed with 4% Paraformaldehyde Fixative (MUTO Pure Chemicals) at 4°C for 30 min. After fixation, cells were treated with 0.4% Triton X-100 in PBS for 15 min at room temperature. After blocked with ImmunoBlock (DS Pharma Biomedical) for 5 min three times, cells were incubated at 4°C overnight with the primary antibodies, followed by washing with the blocking medium and incubation at room temperature for 60 min with the corresponding secondary antibodies. The immunostaining was performed using the following primary antibodies and reagents: anti-α-Actinin (A7811, Sigma-Aldrich), anti-ANP (sc-20130, Santa Cruz), anti- Troponin-I (ab32062, Abcam), anti-GATA4 (sc-1237, Santa Cruz), anti- Nkx2.5 (sc-8697, Santa Cruz), anti- Titin (HPA007042, Sigma-Aldrich), anti- SERCA2 (MAB2630, Millipore), anti-Connexin43 (6219, Sigma-Aldrich), anti-Na/Ca exchanger (MA3-926), and 4’-6-Diamidino-2-Phenylindole (DAPI, Molecular Probes). The secondary antibodies used were anti-rabbit IgG and anti-mouse IgG or IgM conjugated with Alexa Fluor 488 or Alexa Fluor 568 (Molecular Probes). Signal was detected using a conventional fluorescence laser microscope equipped with a colour charge-coupled device camera (BZ-9000, KEYENCE).

Electron microscopy

Contracting EBs were fixed with 2.5% glutaraldehyde in 60 mM HEPES, pH 7.4 for 120 min at room temperature, and washed three times with 0.2 M phosphate buffer. Cells were post-fixed in 1% OsO4 in 60 mM HEPES, pH 7.4 for 120 min at room temperature, and stained en bloc in 2% uranyl acetate for 30 min at room temperature. Tissues were dehydrated with gradually increasing concentrations of ethanol for resin embedding, before thin sectioning and staining.

Field potential recordings using the on-chip multi-electrode array system

Multi-electrode array (MEA) chips from Multi Channel Systems were coated with fibronectin (Sigma-Aldrich). Beating EBs were plated and incubated at 37°C, and MEA measurements were performed at 37°C, as previously described [7]. The signals were initially processed, and the obtained data were subsequently analyzed with MC Rack (Multi Channel Systems). Data for analysis were extracted from 2–5 min of the obtained data. The recorded extracellular electrograms were used to determine local field potential duration (FPD), defined as the time interval between the initial deflection of the field potential (FP) and the maximum local T wave. FPD measurements were normalized (corrected FPD: cFPD) to the activation rate using Bazett’s correction formula: cFPD = FPD/(RR interval) 1/2, where RR represents the time interval (in seconds) between two consecutive beats. Isoproterenol hydrochloride (Sigma-Aldrich), E4031 (Sigma-Aldrich), and verapamil hydrochloride (Sigma-Aldrich) were prepared as 1 or 10 mM stock solutions. The FPs were recorded for 5 min, and then drug was added to the medium. After 2–3 min of incubation, the FPs were again measured for 5 min.

Ca2+ Imaging

For calcium imaging, beating EBs were manually dissected and digested with collagenase 4 (Gibco) at 0.1 mg/ml in ADS buffer (116.4 mM NaCl, 5.4 mM KCl, 5.6 mM dextrose, 10.9 mM NaH2PO4, 405.7 μM MgSO4, and 20 mM HEPES, pH 7.3) and plated onto gelatin-coated dishes in differentiation medium. After 7 days in culture the beating cardiomyocyte clusters were loaded with 6 μg/ml Fluo-4 AM (Invitrogen) for 10 min at 37°C. Ca2+ transients were recorded in iPSC-CMs using an LSM-710 laser
Figure 1. Characterization of in vitro cardiac-differentiation ability of TiPSCs. (A) Morphologies of EBs derived from T07. Scale bar shows 500 μm. (B) Rate of beating EBs derived from ESCs, fibroblast-derived iPSCs line F16, and TiPSC lines T05 and T07 on day 7, day 14, and day 21 of suspension culture. (C) Gene-expression patterns during cardiomyocyte differentiation of TiPSC line T07 and ESCs. Results of QT-PCR studies showed...
scanning confocal microscope (Carl Zeiss), and images were acquired in the line-scan mode.

Results

Characterization of in vitro cardiac differentiation ability of TiPSCs

First, we examined the in vitro cardiac differentiation ability of TiPSCs. We used suspension culture to induce the TiPSCs to form beating EBs, as shown previously for ESCs and iPSCs [28]. The TiPSCs made beating EBs in the same way as ESCs and fibroblast-derived iPSCs (Figure 1A, 1B, Movie S1), confirming that TiPSCs could differentiate into beating cardiomyocytes in suspension culture in vitro.

We also examined the temporal gene expression pattern of derivatives of TiPSCs and ESCs during the in vitro differentiation process. While the expression of undifferentiated pluripotent markers OCT3/4, NANOG, and SOX2 decreased similarly, the cardiac-associated transcription factors, NKX2.5 and MEF2C, and the cardiac-specific structural genes, αMHC and MLC2V, showed high expression in the late stages of floating culture (Figure 1C). On the other hand, primitive streak, mesoderm, and cardiomesoderm markers, MESP1 and BRACHYURY, showed transient expression at the early stage of differentiation (Figure 1C). These results indicated that the expression patterns of undifferentiated and cardiac markers in the derivatives of TiPSCs and ESCs were similar to that observed during embryonic development.

Molecular and cellular characterization of TiPSC-CMs

We next examined expression of the cardiac-specific markers of TiPSC-CMs by further analyzing the derived beating EBs. RT-PCR revealed that our TiPSC-CMs properly expressed cardiomyocyte markers and showed decreased pluripotent marker expression (Figure 2A). Immunostaining confirmed the proper expression of cardiomyocyte markers, α-Actinin, Troponin-I, Titin, ANP, GATA4, and Nkx2.5 in the TiPSC-CMs (Figure 2B).

We then checked the expression of proteins associated with the functionality of cardiomyocytes other than sarcomeric components in TiPSC-CMs. Connexin43 is the most abundant connexin in the ventricular myocardium; it constitutes gap junctions, which are localized to the cardiomyocyte plasma membrane and electrically couple cardiomyocytes to orchestrate action potential propagation [29]. Immunostaining revealed that Connexin43 to the cardiomyocyte plasma membrane and to the intercellular junctional regions in TiPSC-CMs, suggesting the proper development of gap junctions and intact electric coupling (Figure 3A). The activity of the cardiac sarcoplasmic reticulum Ca\(^{2+}\) transport ATPase (SERCA2a) and Na\(^+\)-Ca\(^{2+}\) exchanger controls cardiomyocyte relaxation and contraction by regulating intracellular Ca\(^{2+}\) [30]. In our TiPSC-CMs, SERCA2a was localized to the cytoplasm and Na\(^+\)-Ca\(^{2+}\) exchanger was localized to the plasma membrane (Figure 3A). Electron microscopy of the TiPSC-CMs revealed subcellular morphology identical to that observed in native cardiomyocytes such as the sarcomeric organization and gap junctions (Figure 3B). Ca\(^{2+}\) oscillations are part of the fully

Figure 2. Cardiac-specific markers in TiPSC-CMs. (A) RT-PCR analyses of beating EBs derived from T05 and T07 for the pluripotent marker genes OCT3/4, NANOG, and REX1, the cardiac-related transcription factors GATA4 and MEF2C, and the cardiac-specific marker genes ANP, αMHC, βMHC, MLC2A, MLC2V, cTNNI, and SCN5A. (B) Immunofluorescence staining for cardiac-specific markers in cardiomyocytes derived from T07. Scale bar shows 50 µm.

doi:10.1371/journal.pone.0085645.g002
differentiated cardiac phenotype and key to controlled cardiomyocyte relaxation and contraction. To evaluate intracellular Ca\(^{2+}\) behavior, Ca\(^{2+}\) transients were measured from spontaneously contracting TiPSC-CMs using Fluo-4AM. Line-scan images of Ca\(^{2+}\) transient and its average fluorescence intensity in TiPSC-CMs showed Ca\(^{2+}\) oscillations (Figure 3C) that indicate electrophysiological function typical of native cardiomyocytes. These findings indicated that the generated TiPSC-CMs were functional in regulating intracellular Ca\(^{2+}\).

Pharmacological characterization of TiPSC-CMs

To further evaluate the functionality of TiPSC-CMs, we examined the pharmacological effects of various cardioactive drugs by measuring FPs of the spontaneously beating EBs (Movie S2). To check the response to adrenergic stimulation, we added isoproterenol to the beating EBs derived from TiPSCs, and found a dose-dependent increase in beating frequency, indicating an intact \(\beta\)-adrenergic signaling cascade (Figure 4A). Next, we investigated the effects of ion channel-specific inhibitors on the FP waveform, to determine whether TiPSC-CMs show a native cardiomyocyte-like response to ion channel-specific inhibitors. The IKr blocker E4031 dose-dependently prolonged FPDs in the TiPSCs-CMs (Figure 4B), and the L-type calcium channel blocker, verapamil dose-dependently shortened the length of FPD (Figure 4C). These results indicated that the TiPSC-CMs have identical electrophysiological responses to native cardiomyocytes.
Discussion

The cardiac differentiation ability of iPSCs and functionality of human iPSCs-derived cardiomyocytes have been characterized in previous reports [6,7,31,32]. However, the only evaluation of functionality in derivatives of human pluripotent stem cells that contain genomic rearrangements in the TCR gene locus was in hematopoietic cells derived from human TiPSCs [33]. TiPSC differentiation into the three germ-cell layers was shown for in vivo teratoma formation [23,34–37], and mouse mature T cells that contained genomic rearrangements in the TCR gene locus successfully generated monoclonal mice by the nuclear transfer method [38]. However, the functionality of cardiomyocytes differentiated from human TiPSCs in vitro has not been evaluated. In the present study, we demonstrated several characteristics in TiPSC-CMs that are seen in native cardiomyocytes, and also were previously described as cardiac-specific and essential characters in ESC-CMs and iPSC-CMs without genomic rearrangement [6,39]. Our results thus confirm the potential application of TiPSCs to clinical regenerative therapy for cardiovascular disease and to cardiac disease modeling.

For cardiac cell-based drug screens and cardiac disease research, the minimally invasive methods for tissue sampling involved in generating TiPSCs would be useful for increasing the number of patients who could be subjected to iPSC generation. Our results confirmed the potential of TiPSC-CMs as a cell source of cardiomyocytes with electrophysiological features resembling those of native cardiomyocytes. Therefore, TiPSC-CMs are possible and appealing cell sources for cardiac cell-based drug screens and cardiac disease research.

On another front, TiPSC-CMs have two advantages for transplantation therapy. First, the descendents of TiPSCs that transform into malignant tumors are easily identifiable by their rearrangement patterns. When iPSC-CMs obtained from dermal fibroblasts or other somatic cells are transplanted into diseased patients, there is no good procedure for following the progenies. In animal models, several marker genes can be used to chart the patients, there is no good procedure for following the progenies. Our results thus confirm the potential application of TiPSCs to clinical regenerative therapy for cardiovascular disease and to cardiac disease modeling.

In conclusion, TiPSC-CMs have the potential to provide a unique and valuable cell source for clinical regenerative therapy in cardiovascular disease and for cardiac disease modeling.

Supporting Information

Movie S1 The beating EB derived from TiPSCs in suspension culture. (WMV)

Movie S2 The beating EB derived from TiPSCs on MEA chips. (WMV)

Table S1 Oligonucleotide primers used for PCR. (DOCX)

Acknowledgments

We thank Toshihiro Nagai in the Electron Microscope Laboratory, Keio University School of Medicine for technical assistance with electron microscopy.

Author Contributions

Conceived and designed the experiments: T. Seki SY KM TF. Performed the experiments: T. Seki SY KM TF. Analyzed the data: T. Seki. Contributed reagents/materials/analysis tools: DK AK YS ST KY Y. Kishino MO HH MT TE. Wrote the paper: T. Seki SY JF.

References

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, et al. (2011) Heart disease and stroke statistics–2011 update: a report from the American Heart Association. Circulation 123: e18–e209.
2. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663–676.
3. Bellin M, Marchetto MC, Gage FH, Mummery CL (2012) Induced pluripotent stem cells: the new patient? Nat Rev Mol Cell Biol 13: 713–726.
4. Yuasa S, Fukuda K (2008) Recent advances in cardiovascular regenerative medicine: the induced pluripotent stem cell era. Expert Rev Cardiovasc Ther 6: 803–810.
5. Choi SH, Jung SY, Kwon SM, Baek SH (2012) Perspectives on stem cell therapy for cardiac regeneration. Advances and challenges. Circ J 76: 1307–1312.
6. Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, et al. (2009) Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 104: e30–e41.
7. Tanaka T, Tokuyama S, Murata M, Nomura F, Kaneko T, et al. (2009) In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. Biochem Biophys Res Commun 385: 497–502.
8. Malan D, Friedrichs S, Fleischmann BK, Susse P (2011) Cardiomyocytes obtained from induced pluripotent stem cells with long-QT syndrome 3 recapitulate typical disease-specific features in vitro. Circ Res 109: 841–847.
9. Novak A, Barad L, Zeevi-Levin N, Shick R, Shtrichman R, et al. (2012) Cardiomyocytes generated from CPVTD030/0 patients are arrhythmogenic in response to beta-adrenergic stimulation. J Cell Mol Med 16: 406–412.
10. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, et al. (2010) Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 363: 1397–1409.
11. Ma D, Wei H, Lu J, Ho S, Zhang G, et al. (2013) Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 34: 1122–1133.
12. Yazawa M, Hsueh B, Jia X, Piscia AM, Bernstein JA, et al. (2011) Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 471: 230–234.
13. Sun N, Yazawa M, Liu J, Han L, Sanchez-Freire V, et al. (2012) Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med 4: 130ra147.
14. Lan F, Lee AS, Liang P, Sanchez-Freire V, Nguyen PK, et al. (2013) Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 12: 101–113.
15. Carvajal-Vergara X, Sevilla A, D’Souza SL, Ang YS, Schan菲尔 C, et al. (2010) Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 465: 808–812.
16. Zwi-Dannius L, Huber I, Habib M, Winterstern A, Gepstein A, et al. (2013) Derivation and cardiomyocyte differentiation of induced pluripotent stem cells from heart failure patients. Eur Heart J 34: 1575–1586.
17. Kawanuma M, Miyagawa S, Miki K, Saito A, Fukushima S, et al. (2012) Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation 126: S29–37.
18. Sinnecker D, Goedel A, Laugwitz KL, Moretti A (2013) Induced pluripotent stem cell-derived cardiomyocytes: a versatile tool for arrhythmia research. Circ Res 112: 961–968.

19. Knollmann BC (2013) Induced pluripotent stem cell-derived cardiomyocytes: boutique science or valuable arrhythmia model? Circ Res 112: 969–976; discussion 976.

20. Egashira T, Yuasa S, Fukuda K (2013) Novel insights into disease modeling using induced pluripotent stem cells. Biol Pharm Bull 36: 182–186.

21. Gonzalez F, Bose S, Izpisua Belmonte JC (2013) Methods for making induced pluripotent stem cells: reprogramming a la carte. Nat Rev Genet 12: 231–242.

22. Yamanaka S (2010) Patient-specific pluripotent stem cells become even more accessible. Cell Stem Cell 7: 1–2.

23. Seki T, Yuasa S, Oda M, Egashira T, Yae K, et al. (2010) Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 7: 11–14.

24. Egashira T, Yuasa S, Suzuki T, Aizawa Y, Yamanaka H, et al. (2012) Disease characterization using LQTS-specific induced pluripotent stem cells. Cardiovasc Res 95: 419–429.

25. Suemori H, Yasuchika K, Hasegawa K, Fujioka T, Tsuneyoshi N, et al. (2006) Efficient establishment of human embryonic stem cell lines and long-term maintenance with stable karyotype by enzymatic bulk passage. Biochem Biophys Res Commun 345: 926–932.

26. Conner DA (2001) Mouse embryo fibroblast (MEF) feeder cell preparation. Curr Protoc Mol Biol Chapter 23: Unit 23 22.

27. Tran TH, Wang X, Brown C, Zhang Y, Schinke M, et al. (2009) Wnt3a-induced mesoderm formation and cardiomyogenesis in human embryonic stem cells. Stem Cells 27: 1869–1878.

28. Kelat I, Keryagn-Karsen D, Snir M, Segev H, Amit M, et al. (2001) Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 108: 407–414.

29. Smyth JW, Shaw RM (2012) The gap junction life cycle. Heart Rhythm 9: 151–153.

30. Schaub MC, Hefti MA, Zangg M (2006) Integration of calcium with the signaling network in cardiac myocytes. J Mol Cell Cardiol 43: 183–214.

31. Zvi L, Caspi O, Arbel G, Huber I, Grinstein A, et al. (2009) Cardiomyocyte differentiation of human induced pluripotent stem cells. Circulation 120: 1513–1523.

32. Germangui E, Sedan O, Zevri-Levin N, Shtrichman R, Barak E, et al. (2011) Molecular characterization and functional properties of cardiomyocytes derived from human inducible pluripotent stem cells. J Cell Mol Med 15: 38–51.

33. Kajiwara M, Aoi T, Okita K, Takahashi K, Inoue H, et al. (2012) Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells. Proc Natl Acad Sci U S A 109: 12530–12534.

34. Staerk J, Dawlaty MM, Gao Q, Maetzel D, Hanna J, et al. (2010) Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell 7: 20–24.

35. Lob YH, Hartung O, Li H, Guo C, Sahalie JM, et al. (2010) Reprogramming of T cells from human peripheral blood. Cell Stem Cell 7: 15–19.

36. Kunisato A, Wakatsuki M, Shinba H, Ota T, Ishida I, et al. (2011) Direct generation of induced pluripotent stem cells from human nonmobilized blood. Stem Cells Dev 20: 159–168.

37. Brown ME, Rondon E, Rajesh D, Mack A, Lewis R, et al. (2010) Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes. PLoS One 5: e11373.

38. Hochedlinger K, Jaenisch R (2002) Monoclonal mice generated by nuclear transfer from mature B and T donor cells. Nature 415: 1035–1038.

39. Mummery C, Ward D, van den Brink CE, Bird SD, Doevendans PA, et al. (2002) Cardiomyocyte differentiation of mouse and human embryonic stem cells. J Anat 200: 233–242.

40. Nakatsuji N, Nakajima F, Tokunaga K (2008) HLA-haplotype banking and iPS cells. Nat Biotechnol 26: 739–740.